The Claim
In obese male mice, combination treatment with semaglutide and dual GDF8/activin A blockade results in approximately twice the fat mass loss over four weeks compared to semaglutide monotherapy, despite equivalent overall weight reduction, suggesting that muscle preservation may enhance fat mobilization.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese male mice, combining semaglutide with a treatment that blocks GDF8 and activin A leads to about twice as much fat loss over four weeks compared to semaglutide alone, even when total weight loss is the same, indicating that preserving muscle may help the body remove more fat.
See the scientific wording
In obese male mice, combination treatment with semaglutide and dual GDF8/activin A blockade results in approximately twice the fat mass loss compared to semaglutide alone over four weeks, despite similar overall weight reduction, indicating that muscle preservation may enhance fat mobilization.
What the research says
1 studyWhen mice were given a weight-loss drug plus a treatment that stops muscle loss, they lost twice as much fat as mice given just the weight-loss drug — even though both groups lost the same total weight. This means keeping muscle helps the body burn more fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.